X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.01M | 35.11M | 33.98M | 32.77M | 31.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.01M | 35.11M | 33.98M | 32.77M | 31.36M |
| Cost of Revenue | 1.64M | 5.76M | 5.70M | 5.57M | 5.51M |
| Gross Profit | 7.38M | 29.36M | 28.28M | 27.20M | 25.85M |
| SG&A Expenses | 32.02M | 40.12M | 47.88M | 55.35M | 59.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 102.02M | 117.30M | 127.98M | 138.66M | 144.92M |
| Operating Income | -93.01M | -82.18M | -94.00M | -105.89M | -113.56M |
| Income Before Tax | -99.72M | -79.16M | -94.80M | -101.63M | 14.92M |
| Income Tax Expenses | 7.00K | 41.00K | 299.00K | 344.00K | 325.00K |
| Earnings from Continuing Operations | -99.72 | -79.20 | -95.10 | -101.98 | 14.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.72M | -79.20M | -95.10M | -101.98M | 14.60M |
| EBIT | -93.01M | -82.18M | -94.00M | -105.89M | -113.56M |
| EBITDA | -91.99M | -80.91M | -92.67M | -104.52M | -112.35M |
| EPS Basic | -4.75 | -4.55 | -10.01 | -14.80 | 2.27 |
| Normalized Basic EPS | -2.90 | -2.77 | -6.15 | -9.22 | -8.37 |
| EPS Diluted | -4.75 | -4.55 | -10.01 | -14.80 | 2.24 |
| Normalized Diluted EPS | -2.90 | -2.77 | -6.15 | -9.22 | -8.37 |
| Average Basic Shares Outstanding | 288.42M | 168.97M | 64.29M | 27.71M | 26.98M |
| Average Diluted Shares Outstanding | 288.42M | 169.00M | 64.32M | 27.74M | 27.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |